Laboratories And Cipla

'Laboratories And Cipla' - 17 News Result(s)

  • Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
    India News | Reuters | Tuesday June 29, 2021
    Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
    www.ndtv.com
  • Sensex, Nifty Fall For Fifth Day In A Row; Pharma Stocks Lead Declines
    Business | NDTV Profit Team | Monday May 21, 2018
    The stock markets extended losses to a fifth straight session, with BSE benchmark index Sensex closing 232 points lower on Monday. While the 30-scrip Sensex settled at 34,616, the NSE Nifty ended 79 points lower at 10,516. A selloff witnessed in pharma, metal, auto and realty shares dragged the key indices lower. Top laggards on the NSE Nifty inclu...
    www.ndtv.com/business
  • Indian Pharma's Focus On Acquisitions To Limit Deleveraging: Fitch
    Business | Press Trust of India | Tuesday November 15, 2016
    New Delhi: In line with global trends in thepharmaceuticals sector, the focus of domestic drug firms on acquisitionsto consolidate their position will limit deleveraging for thetime being, rating agency Fitch has said. "The ongoing focus of the top Indian pharma companies' onselective acquisitions to limit deleveraging over the shortterm," Fitch...
    www.ndtv.com/business
  • Dr Reddy's, Cipla, Aurobindo Among Others To Buy Products From Teva
    Business | Press Trust of India | Friday July 29, 2016
    Dr Reddy's laboratories, Cipla and Aurobindo Pharma are among 11 firms that may acquire 79 existing and future drugs from Teva Pharmaceuticals as part of the condition set by the US Federal Trade Commission for $40.5 billion Teva-Allegran deal.
    www.ndtv.com/business
  • Prices Of Cancer, Diabetes, Blood Pressure Drugs Cut By Around 25%
    Business | Press Trust of India | Monday June 6, 2016
    Prices of 56 important medicines used in treatment of cancer, diabetes, bacterial infections and blood pressure have been capped by the government thereby reducing the cost by an average of around 25 per cent.
    www.ndtv.com/business
  • Pharma Pricing Authority Caps Price of 18 Formulations Packs
    Business | Press Trust of India | Sunday November 1, 2015
    Drug firms such as Cipla, Alembic Pharma and Unichem Laboratories will be impacted by the government's move for prices fixation and revision.
    www.ndtv.com/business
  • Government Caps Price of 18 Formulation Packs
    Business | Press Trust of India | Wednesday August 26, 2015
    The government has brought 18 more drugs, used to treat cancer, inflammation and infections, among others, under price control as part of its efforts to make life saving medicines affordable in the country.
    www.ndtv.com/business
  • 2014: Pharma Deals Worth Billions, Fines Worth Millions
    Business | Saturday December 27, 2014
    It has been a year of bitter medicine for Indian pharmaceutical companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including a high profile merger between Sun Pharma and Ranbaxy.
    www.ndtv.com/business
  • Prices of 36 More Drugs Capped to Improve Access: Report
    Business | Friday September 19, 2014
    Drugmakers, including Cipla Ltd, Ranbaxy Laboratories Ltd, and Cadila Healthcare Ltd are among the companies that will be affected by the latest decision, research firm AIOCD Pharmasofttech AWACS Pvt Ltd said.
    www.ndtv.com/business
  • US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
    Business | Monday September 15, 2014
    US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
    www.ndtv.com/business
  • 2013: Few bitter pills, booster injections for pharma sector
    Business | Sunday December 29, 2013
    Domestic firms coming under increased scrutiny of global regulators, resulting in Ranbaxy paying a record $500-million fine, and drugs becoming cheaper in India thanks to a new pricing policy marked a roller-coaster year 2013 for the pharma industry.
    www.ndtv.com/business
  • Ranbaxy drugs are 'safe and efficacious': South Africa
    Business | Wednesday June 5, 2013
    The South African subsidiary of India's largest pharmaceutical company has also issued a similar statement, assuring the public that drugs manufactured locally are safe.
    www.ndtv.com/business
  • Pharma stocks gain on value-buying
    Business | Tuesday June 4, 2013
    Shares in pharmaceutical companies are leading the gains on Tuesday due to factors such as value-buying and expectations that promoters may increase stake in some companies, dealers say.
    www.ndtv.com/business
  • Top generic drugmakers look to US as patents end
    Business | Wednesday May 8, 2013
    India's top drugmakers, among the world's biggest producers of cheap generic medicines, are looking beyond their own shores to generate revenue, seeking to profit from big-selling drugs going off-patent this year in the lucrative U.S. market.
    www.ndtv.com/business
  • Nomura upgrades Ranbaxy to 'buy' on expectations of better margins
    Business | Monday March 11, 2013
    Global brokerage Nomura has upgraded the stock of drug major Ranbaxy to a buy from neutral, and set its 12-month target price at Rs 475.
    www.ndtv.com/business

'Laboratories And Cipla' - 3 Video Result(s)

'Laboratories And Cipla' - 17 News Result(s)

  • Five Indian Drugmakers To Jointly Start Trial Of Merck & Co's Covid Drug
    India News | Reuters | Tuesday June 29, 2021
    Fivegeneric drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in the country.
    www.ndtv.com
  • Sensex, Nifty Fall For Fifth Day In A Row; Pharma Stocks Lead Declines
    Business | NDTV Profit Team | Monday May 21, 2018
    The stock markets extended losses to a fifth straight session, with BSE benchmark index Sensex closing 232 points lower on Monday. While the 30-scrip Sensex settled at 34,616, the NSE Nifty ended 79 points lower at 10,516. A selloff witnessed in pharma, metal, auto and realty shares dragged the key indices lower. Top laggards on the NSE Nifty inclu...
    www.ndtv.com/business
  • Indian Pharma's Focus On Acquisitions To Limit Deleveraging: Fitch
    Business | Press Trust of India | Tuesday November 15, 2016
    New Delhi: In line with global trends in thepharmaceuticals sector, the focus of domestic drug firms on acquisitionsto consolidate their position will limit deleveraging for thetime being, rating agency Fitch has said. "The ongoing focus of the top Indian pharma companies' onselective acquisitions to limit deleveraging over the shortterm," Fitch...
    www.ndtv.com/business
  • Dr Reddy's, Cipla, Aurobindo Among Others To Buy Products From Teva
    Business | Press Trust of India | Friday July 29, 2016
    Dr Reddy's laboratories, Cipla and Aurobindo Pharma are among 11 firms that may acquire 79 existing and future drugs from Teva Pharmaceuticals as part of the condition set by the US Federal Trade Commission for $40.5 billion Teva-Allegran deal.
    www.ndtv.com/business
  • Prices Of Cancer, Diabetes, Blood Pressure Drugs Cut By Around 25%
    Business | Press Trust of India | Monday June 6, 2016
    Prices of 56 important medicines used in treatment of cancer, diabetes, bacterial infections and blood pressure have been capped by the government thereby reducing the cost by an average of around 25 per cent.
    www.ndtv.com/business
  • Pharma Pricing Authority Caps Price of 18 Formulations Packs
    Business | Press Trust of India | Sunday November 1, 2015
    Drug firms such as Cipla, Alembic Pharma and Unichem Laboratories will be impacted by the government's move for prices fixation and revision.
    www.ndtv.com/business
  • Government Caps Price of 18 Formulation Packs
    Business | Press Trust of India | Wednesday August 26, 2015
    The government has brought 18 more drugs, used to treat cancer, inflammation and infections, among others, under price control as part of its efforts to make life saving medicines affordable in the country.
    www.ndtv.com/business
  • 2014: Pharma Deals Worth Billions, Fines Worth Millions
    Business | Saturday December 27, 2014
    It has been a year of bitter medicine for Indian pharmaceutical companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including a high profile merger between Sun Pharma and Ranbaxy.
    www.ndtv.com/business
  • Prices of 36 More Drugs Capped to Improve Access: Report
    Business | Friday September 19, 2014
    Drugmakers, including Cipla Ltd, Ranbaxy Laboratories Ltd, and Cadila Healthcare Ltd are among the companies that will be affected by the latest decision, research firm AIOCD Pharmasofttech AWACS Pvt Ltd said.
    www.ndtv.com/business
  • US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
    Business | Monday September 15, 2014
    US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
    www.ndtv.com/business
  • 2013: Few bitter pills, booster injections for pharma sector
    Business | Sunday December 29, 2013
    Domestic firms coming under increased scrutiny of global regulators, resulting in Ranbaxy paying a record $500-million fine, and drugs becoming cheaper in India thanks to a new pricing policy marked a roller-coaster year 2013 for the pharma industry.
    www.ndtv.com/business
  • Ranbaxy drugs are 'safe and efficacious': South Africa
    Business | Wednesday June 5, 2013
    The South African subsidiary of India's largest pharmaceutical company has also issued a similar statement, assuring the public that drugs manufactured locally are safe.
    www.ndtv.com/business
  • Pharma stocks gain on value-buying
    Business | Tuesday June 4, 2013
    Shares in pharmaceutical companies are leading the gains on Tuesday due to factors such as value-buying and expectations that promoters may increase stake in some companies, dealers say.
    www.ndtv.com/business
  • Top generic drugmakers look to US as patents end
    Business | Wednesday May 8, 2013
    India's top drugmakers, among the world's biggest producers of cheap generic medicines, are looking beyond their own shores to generate revenue, seeking to profit from big-selling drugs going off-patent this year in the lucrative U.S. market.
    www.ndtv.com/business
  • Nomura upgrades Ranbaxy to 'buy' on expectations of better margins
    Business | Monday March 11, 2013
    Global brokerage Nomura has upgraded the stock of drug major Ranbaxy to a buy from neutral, and set its 12-month target price at Rs 475.
    www.ndtv.com/business

'Laboratories And Cipla' - 3 Video Result(s)

Your search did not match any documents
A few suggestions
  • Make sure all words are spelled correctly
  • Try different keywords
  • Try more general keywords
Check the NDTV Archives:https://archives.ndtv.com